Objective:

The video interview covers Nucleome Therapeutics’ use of Micro Capture-C to reconstruct DNA’s three-dimensional architecture and identify causal disease biology, as well as Jonny Wray’s engineering-led approach to platform biotechnology.

Approach:

• Technology: Nucleome Therapeutics uses Micro Capture-C to reconstruct DNA’s three-dimensional architecture and investigate causal disease biology.
• Company philosophy: Wray describes an engineering-led approach focused on finding workable solutions rather than understanding every detail.

Key Findings:

• Nucleome Therapeutics aims to use Micro Capture-C to uncover overlooked drug targets and improve the chances of clinical success.
• Wray’s career has spanned electronic engineering, computational neuroscience, and drug discovery, driven by an interest in cutting-edge work that addresses important problems.
• Wray says platform biotechs should develop differentiated technologies that address drug discovery bottlenecks and demonstrate value along the way.

Interpretation:

The interview describes Micro Capture-C as a means of studying DNA architecture and identifying causal disease biology, and presents Wray’s practical, engineering-led philosophy for developing platform technologies.

Limitations:

• The provided context does not report study data, performance measures, or clinical outcomes.

Conclusion:

Wray discusses how Nucleome Therapeutics uses Micro Capture-C to investigate disease biology and how platform biotechs can address drug discovery bottlenecks while demonstrating value.

Sources:

• Article context